Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Journal article

BACKGROUND: The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD. METHODS: 210 patients living in the community who had a mini-mental state examination (MMSE) score of 15-26 were randomly assigned to receive tarenflurbil twice per day (400 mg [n=69] or 800 mg [n=70]) or placebo (n=71) for 12...

Expand abstract

Authors: Wilcock, G; Black, SE; Hendrix, S; Zavitz, K; Swabb, E

• Publication status: Published
• Journal: Lancet. Neurology
• Volume: 7
• Issue: 6
• Pages: 483-493
• Publication date: 2008-06-01
• DOI: 10.1016/s1474-4422(08)70090-5
• EISSN: 1474-4465
• ISSN: 1474-4422
• Language: English
• Keywords: Amyloid Precursor Protein Secretases; Amyloid beta-Peptides; Placebo Effect; Female; Dose-Response Relationship, Drug; Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Tarenflurbil Phase II Study investigators; Aged, 80 and over; Nausea; Middle Aged; Treatment Outcome; Male; Disease Progression; Humans; Aged; Great Britain; Alzheimer Disease; Brain; Flurbiprofen; Diarrhea; Canada; Drug Administration Schedule